A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.

Aún no traducido Aún no traducido
Categoría Revisión sistemática
RevistaHealth technology assessment (Winchester, England)
Año 2006
Enlaces Pubmed, DOI

Este artículo está incluido en 1 Resumen estructurado de revisiones sistemáticas 30 Resúmenes estructurados de revisiones sistemáticas (1 referencia) 3 Síntesis amplias 30 Síntesis amplias (3 referencias)

Este artículo incluye 36 Estudios primarios 30 Estudios primarios (36 referencias)

Este artículo es parte de los siguientes hilos de publicación
Este artículo es parte de las siguientes matrices de evidencia
Cargando información sobre las referencias

OBJECTIVES:

This report reviews the clinical effectiveness and cost-effectiveness of adalimumab, etanercept and infliximab, agents that inhibit tumour necrosis factor-alpha (TNF-alpha), when used in the treatment of rheumatoid arthritis (RA) in adults.

DATA SOURCES:

Electronic databases were searched up to February 2005.

REVIEW METHODS:

Systematic reviews of the literature on effectiveness and cost-effectiveness were undertaken and industry submissions to the National Institute for Health and Clinical Excellence (NICE) were reviewed. Meta-analyses of effectiveness data were also undertaken for each agent. The Birmingham Rheumatoid Arthritis Model (BRAM), a simulation model, was further developed and used to produce an incremental cost-effectiveness analysis.

RESULTS:

Twenty-nine randomised controlled trials (RCTs), most of high quality, were included. The only head-to-head comparisons were against methotrexate. For patients with short disease duration (






Epistemonikos ID.: fa341b1071144639f2b733e59cd0c2cb35f61029


First added on: Sep 01, 2014